The main goal of the study is to see whether a single dose of the medicine is safe and whether it can raise protein levels to a normal range, with some participants receiving a second dose later to assess longer‑term effects. Participants will receive the infusion, then attend regular visits over several months during which blood samples and simple health checks are performed.

Researchers will watch for any side effects, measure the amount of the protective protein in the blood, and test how well it works using a laboratory test called a elastase inhibition assay. They will also check lung function and liver health through routine exams and questionnaires to understand how the treatment impacts overall well‑being.

The purpose of the study is to assess the safety of using Prolastin for self-infusion therapy at home over a period of 12 weeks. Participants will be trained to perform the infusions themselves or with the help of a caregiver. The study will monitor the occurrence of any adverse effects during the training and main study period. Additionally, it will evaluate various health parameters, such as lung function and patient satisfaction, to understand the impact of the treatment.

Throughout the study, participants will have regular visits to assess their health and the ease of using the treatment. The study aims to provide valuable information on how safe and effective it is for patients with Severe Alpha-1 Antitrypsin Deficiency to manage their condition with home-based self-infusion therapy using Prolastin.

The purpose of the study is to evaluate the safety and tolerability of WVE-006 in participants with a specific genetic form of AATD, known as Pi*ZZ. Participants will receive either single or multiple doses of WVE-006. The study will monitor how the body processes the medication and any potential side effects. Participants will receive the medication through a subcutaneous injection, which means it is injected under the skin.

Throughout the study, researchers will observe changes in the levels of a protein called M-AAT in the blood, which is related to the condition. The study will also measure how much of the medication is present in the blood over time. This research aims to gather important information about how WVE-006 works in people with AATD and to ensure it is safe for use. The study is expected to continue until the end of 2025.

The purpose of the study is to evaluate the safety and effectiveness of BEAM-302 in adults with AATD-associated lung and/or liver disease. The study is divided into two phases. The first phase will explore different doses to determine the safest and most effective amount of the treatment. The second phase will expand on this by confirming the optimal dose and further assessing how well the treatment works. Participants will receive the treatment and be monitored for any side effects or changes in their condition.

Throughout the study, researchers will collect information on how the treatment affects the levels of certain proteins in the blood, specifically those related to Alpha-1 Antitrypsin. This will help determine the treatment’s impact on the disease. The study aims to provide valuable insights into the potential of BEAM-302 as a treatment option for individuals with AATD-related health issues.

The purpose of the study is to evaluate the long-term safety and tolerability of INBRX-101 in adults with AATD emphysema. Participants in the study will receive the treatment through an infusion, which is a method of delivering medication directly into the bloodstream. The study will monitor participants over a period to observe any side effects and to assess how well the treatment works in managing the condition.

Throughout the study, researchers will keep track of any adverse events, which are any unwanted effects that occur during the treatment. They will also look at changes in lung density using a method called computed tomography (CT), which is a type of imaging that helps visualize the lungs. Additionally, the study will examine how the body processes the treatment and whether any antibodies, which are proteins made by the immune system, develop against INBRX-101. The study aims to provide valuable information on the safety and effectiveness of this treatment for people with AATD emphysema.

The main goal of the study is to evaluate the long-term safety of Fazirsiran, with a special focus on lung health, as the condition can also affect the lungs. Participants in the study will receive either Fazirsiran or a placebo through injections. The study will monitor various health indicators, including lung function and liver health, over a period of time to see how the treatment affects these areas. Participants will undergo regular check-ups and tests to track any changes in their condition.

This study is important for understanding how Fazirsiran can help people with Alpha-1 Antitrypsin Deficiency-Associated Liver Disease and to ensure that it is safe for long-term use. By participating in this trial, researchers hope to gather valuable information that could lead to better treatment options for those affected by this genetic disorder.

Participants in the study will receive either the new treatment, INBRX-101, or the existing A1PI therapy. The study is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving which treatment. This helps ensure that the results are unbiased. The study will also include a placebo group, which will receive a solution that does not contain the active treatment. Throughout the study, participants will have regular check-ups to monitor their health and the effects of the treatment.

The study aims to gather information on the safety and effectiveness of INBRX-101 compared to the current standard treatment. It will also look at how the body processes the new treatment and whether it causes any immune reactions. By the end of the study, researchers hope to better understand if INBRX-101 can be a beneficial treatment option for people with AATD emphysema.

The purpose of the study is to evaluate how effective Fazirsiran is compared to a placebo in improving liver health in people with this condition. Participants in the study will receive either Fazirsiran or a placebo through subcutaneous injections, which means the injection is given under the skin. The study will take place over a period of time, with regular check-ups to monitor the health of the liver and the overall safety of the treatment.

Throughout the study, participants will undergo various assessments to track changes in their liver condition. These assessments will help determine if Fazirsiran can reduce liver scarring and improve liver function. The study aims to provide valuable information on whether this treatment can be a beneficial option for people with Alpha-1 Antitrypsin Deficiency-Associated Liver Disease.

The purpose of this study is to evaluate the long-term safety and effectiveness of Fazirsiran in people with Alpha-1 Antitrypsin Deficiency-Associated Liver Disease. Participants in this study will receive Fazirsiran through subcutaneous injections, which means the medication is injected under the skin. The study will monitor participants over a period of time to observe any changes in their health and to ensure the treatment is safe and well-tolerated.

Throughout the study, participants will have regular check-ups to assess their liver health and overall well-being. This includes monitoring vital signs, conducting laboratory tests, and evaluating liver function. The study aims to provide valuable information on how Fazirsiran can help manage liver disease associated with Alpha-1 Antitrypsin Deficiency over an extended period.